Feb. 23 at 6:33 PM
$FATE Biogen’s M&A "Hunt": Biogen CEO Christopher Viehbacher stated in January 2026 that the company is actively seeking "one more near-term growth asset"—specifically a late Phase 3 or recently launched drug—to offset declining revenue from its legacy multiple sclerosis (MS) franchise.
Target Size and Sector: Biogen has indicated interest in acquisitions valued between
$1 billion and
$6 billion, with a focus on immunology and rare diseases.
Fate’s Pivot to Immunology: Fate Therapeutics has increasingly focused its iPSC-derived cell therapy platform on autoimmune diseases, specifically Systemic Lupus Erythematosus (SLE), which aligns with Biogen’s existing interest in lupus (e.g., its litifolumab program).
